Tesamorelin vs CJC-1295

The Dose Guy’s verdict

Oct 27, 2026
6 sources

For general GH-axis work like recovery, sleep, or a recomp, run CJC-1295, the no-DAC form, with ipamorelin; it does the broader job for less. Tesamorelin wins when visceral belly fat is the specific target, especially if a scan has confirmed it, because it is the one with an approval and real trials behind it. Its catch is that the fat comes back when you stop. Never stack the two, because they push the same button.

Which would I take?CJC for the GH axis, tesa for belly fat.

How they differ

Same mechanism, different receipts. Each one mimics GHRH, the hormone your brain uses to tell the pituitary to release growth hormone, so both are growth-hormone secretagogues: the GH is yours, and the pin only requests it. If you pay more for tesamorelin, you are paying for the evidence, not a different action. It was tested on HIV patients carrying drug-driven fat deep in the abdomen, and the trials tracked that fat shrinking on scans. CJC-1295 has hormone-level numbers in healthy adults and no outcome trial at all.

For fat loss, that makes tesamorelin the pick, but only for the deep belly kind it was tested on; expect it to move your waist more than your scale. For muscle growth, neither has a trial in lifters. Tesamorelin’s lean-mass gain came from HIV patients, and CJC-1295’s case is mechanism plus years of logs. For that goal I would rather run CJC-1295 with ipamorelin, the GHRP partner that turns the GH nudge into a bigger, cleaner pulse.

The rhythm differs too. Tesamorelin is one fixed pin a day, every day, for months. No-DAC CJC-1295 is a pre-bed pin, or a few short ones a day, timed around empty-stomach windows. The DAC form is the low-effort option at one or two pins a week, but it holds GH up between pulses for days, a smeared signal people call GH bleed, and most people who try it go back to no-DAC. So when Reddit pits tesamorelin against the DAC form, the answer holds: DAC for convenience, tesamorelin for belly fat with receipts.

What the research shows

Nobody has run these two against each other, so this is two trial programs side by side, in different people:

No head-to-head trial of tesamorelin against CJC-1295 exists, in either form. The no-DAC CJC-1295 most people run has never been in a human study.as of Aug 2026

Tesamorelin in HIV abdominal fat: a 15.4% treatment effect on visceral fat at 26 weeks versus placebo, and participants continuing to 52 weeks maintained a 17.5% reduction from baseline.JCEM 2010 · pooled phase 3 · n=806

Pooling four RCTs, tesamorelin 2 mg cut visceral fat by 21.47 cm2, trunk fat by 1.20 kg, and raised lean body mass by 1.42 kg versus control.JAIPA 2026 · meta-analysis · 4 RCTs, n=909

The visceral fat improvements were rapidly lost when participants switched from tesamorelin to placebo.JAIDS 2010 · phase 3 · n=404

One sub-q injection of CJC-1295 with DAC raised mean GH two- to tenfold for at least 6 days and IGF-I 1.5- to threefold for 9 to 11 days.JCEM 2006 · RCT · healthy adults

Tesamorelin’s numbers are outcomes in HIV patients; CJC-1295’s are hormone levels in healthy adults on the DAC form. Neither tells you how the two compare in a lifter, so the call rests on the goal.

How people run them

Tesamorelin runs at 2 mg sub-q once a day on an empty stomach, fixed, because the trials used 2 mg flat and that is where the data lives. The trials dosed in the morning; some people pin it pre-bed instead. Plan on 26 weeks or more. No-DAC CJC-1295 runs at about 100 mcg, pre-bed at minimum, two hours or so after your last meal, with ipamorelin in the same syringe and a morning or pre-workout shot added on the full stack. The receptor saturates at a modest dose, so more does not buy proportionally more GH.

Switching from no-DAC CJC-1295 to tesamorelin, take your last pre-bed shot and start tesamorelin the next morning; no washout. From the DAC form, wait a week after the last pin, because it is still working. Ipamorelin can stay in its slots either way. Going from tesamorelin to CJC-1295, usually once the belly target is met or the cost wears thin, start CJC-1295 that night and expect the visceral fat to drift back.

Skip the stack. Both lean on the same GHRH receptor, so the second one costs you pins and adds no GH. If you want the pairing on tesamorelin, ipamorelin is the partner, same as on CJC-1295.

Tesamorelin2 mg/daySub-q, empty stomach, fixed dose; the trials ran 26 to 52 weeks.

CJC-1295 no-DAC100 mcg, 1–3x/dayPre-bed at minimum, same syringe as ipamorelin.

CJC-1295 DAC1–2 mg/wkThe low-effort option, with a blurrier pulse; most people prefer no-DAC.

CJC to tesa2 mg, next morningNo washout from no-DAC; from DAC, start a week after the last pin.

Tesa to CJC100 mcg, that nightThe belly fat tesamorelin took tends to drift back.

Side effects, side by side

Tesamorelin’s sides are written down in trials, CJC-1295’s mostly come from logs, and they look alike:

commonInjection-site redness and irritation on both. Tesamorelin’s trials logged more of it than placebo, none of it serious.

commonJoint pain, muscle aches, and numb or tingling hands, documented on tesamorelin and reported on CJC-1295 along with water retention when GH runs high. Ease back the CJC-1295 dose if they show; tesamorelin’s dose is fixed, so hands that stay numb are a reason to stop.

commonFlushing or a head-rush right after a CJC-1295 shot, brief and harmless.

monitorFasting glucose bumps early on tesamorelin and tends to settle; CJC-1295 nudges blood sugar and insulin sensitivity over time. Check yours on either, especially if it runs borderline.

unknownCJC-1295’s controlled safety record stops at 49 days, and tesamorelin’s long trials are in HIV patients. Nobody has followed healthy lifters on either for years.